Zydus joins once-weekly DPP-4 inhibitor fray
This article was originally published in Scrip
Zydus Cadila has received US FDA approval to initiate Phase I trials for its candidate long-acting dipeptidyl peptidase IV (DPP-4) inhibitor for type 2 diabetes, joining a clutch of firms already in the development fray in the field including Merck & Co and Takeda.
You may also be interested in...
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…
Eisai and partner Sun to take lorcaserin off the Indian market. It remains to be seen whether the Japanese firm sees merit in pursuing a simmering patent infringement suit against Dr Reddy’s, which may need to review its own plans for lorcaserin.